VERTEX PHARMACEUTICALS INC / MA (VRTX) Options Risk Score
Real-time risk analysis for VRTX options traders — updated every 30 minutes.
Data last updated: 2026-07-23
Run a full VRTX options risk analysis
See the complete risk breakdown — news catalysts, SEC filings, legal proceedings, earnings overlap, IV vs HV, options flow and Expected Move — all in one scan.
Scan VRTX Now — Free →
Is it risky to sell options on VERTEX PHARMACEUTICALS INC / MA (VRTX) right now?
VERTEX PHARMACEUTICALS INC / MA (VRTX) currently scores 62 out of 100 for options catalyst risk (MEDIUM) over a 4-week expiry window. That score is driven by an upcoming earnings report, 6 recent news items and 28 clinical-trial catalysts falling inside the 4-week window. On TickerRisk's scale 45 to 69 is MEDIUM, meaning something in the 4-week window is worth checking before committing to an expiry. The score measures scheduled event exposure, not the direction VRTX will move.
VRTX shows an IV Rank of 34, near the low end of its one-year range — options are relatively cheap, which favours option buyers over sellers, with a current implied volatility of about 42%. IV Rank is the most useful figure for deciding whether to sell or buy premium on VRTX.
VRTX is scheduled to report earnings on 2026-08-03, which falls inside a typical monthly options expiry — expect elevated implied volatility into the event and an IV crush afterward.
TickerRisk provides risk scoring for informational purposes only. This is not financial advice. Options trading involves substantial risk of loss. Full disclaimer